神經膠原致癌基因 (HER2/neu) 的穿膜醣蛋白產物分子量約為185仟道爾吞，因此 HER2/neu 也稱為 p185HER2/neu。p185HER2/neu 蛋白屬於上皮生長因子受體 (EGFR) 家族的其中一員，其過度表現常與許多癌症發生有關。黃芩素 (baicalein) 為傳統中草藥上應用廣泛的黃芩根部中一種類黃酮素物質，根據已發表的研究文獻指出，黃芩素可當作抗氧化及抗發炎試劑。此外，黃芩素也有抗癌的效果，但是黃芩素在 p185HER2/neu 過度表現細胞中的抗癌分子機轉值得進一步去探討研究。本論文研究結果顯示，黃芩素可抑制神經膠原致癌基因的表現。此外也深入探討黃芩素在p185HER2/neu 過度表現的 SKOV-3 卵巢癌細胞及中的抗癌效果。實驗結果指出黃芩素在 p185HER2/neu 過度表現的細胞中可以抑制經由神經膠原致癌基因所誘發的轉形能力 (transforming ability)。

HER2, also known as p185HER2/neu, is a transmembrane receptor tyrosine kinase that belongs to the epidermal growth factor receptor (EGFR) family.  Overexpression of the HER2/neu is associated with a wide range of human cancers.  HER2 downstream signal transductions are related to cell proliferation, growth, survival, angiogenesis and metastasis.  Baicalein, a flavonoid, is derived from the root of Scutellaria baicalensis Georgi, a plant traditionally used in Chinese herbal medicine.  According to the literature, baicalein is known as an antioxidant and anti-inflammatory agent.  Besides, it also has other activities such as anticancer effect, but the molecular mechanism of this effect in p185HER2/neu overexpressing cells is still unclear.  Our results showed that baicalein could suppress HER2 gene expression. In addition, We also evaluated the anticancer effects of baicalein on p185HER2/neu overexpressing  SKOV-3 ovarian cancer cells.  Together, these finding suggest that the inhibition of the expression of p185HER2/neu by baicalein is capable of supperssing the HER2/neu-mediated transforming ability in p185HER2/neu overexpressing ovarian cancer cells.

摘要.......................I
  中文摘要.................I
  英文摘要................II
縮寫表....................IV
第一章 緒論................1
  第一節 神經膠原致癌基因..1
  第二節 黃芩素...........15
  第三節 實驗動機與目的...26
第二章 材料與方法.........27
第三章 結果...............34
  第一節 實驗結果.........34
  第二節 實驗圖表.........38
第四章 討論...............46
第五章 參考文獻...........51
附錄一....................61
附錄二....................63

1.Amici, A. et al. (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER2/neu transgenic mice. Gene Ther., 7, 703-706.

2.Aunoble, B et al. (2000) Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer  (review). Int J Oncol., 16, 567-576.

3.Badache, A. and Gonçalves, A. (2006) The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. J. Mammary Gland Biol. Neoplasia., 11, 13-25. 

4.Baselga, J. (2006) Targeting tyrosine kinases in cancer: the second wave. Science., 312, 1175-1178.

5.Baulida, J. et al. (1996) All ErbB receptors other than  the epidermal growth factor receptor are endocytosis  impaired. J. Biol. Chem., 271, 5251-5257.

6.Benusiglio, P.R. (2008) Focus on ERBB2. Pharmacogenomics., 9, 825-828.

7.Chao, J.I. et al. (2007) Baicalein induces cancer cell   death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol. Cancer Ther., 6, 3039-3048.

8.Chen, C.H. et al. (2009) Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem. Toxicol., 47, 638-644.

9.Chiang, C.T. et al. (2007) Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression  with rapamycin. Mol. Cancer Ther., 6, 2127-2138.

10.Chuang, T.C. et al. (2002) The N-terminal domain of SV40 large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers. FEBS Lett., 511, 46-50.

11.Chuang, T.C. et al. (2002) The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett., 532, 135-142.

12.Chuang, T.C. et al. (2003) EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem. Biophys. Res. Commun., 307, 653-659.

13.Chuang, T.C. et al. (2007) Human manganese superoxide   dismutase suppresses HER2/neu-mediated breast cancer malignancy. FEBS Lett., 581, 4443-4449.

14.Chung, H. et al. (2008) Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int. J. Cancer., 122, 816-822.

15.Citri, A. et al. (2002) Drug-induced ubiquitylation   and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J., 21, 2407-2417.

16.Citri, A. and Yarden, Y. (2006) EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 7, 505-516.

17.Coussens, L.M. and Werb, Z (2002) Inflammation and   cancer. Nature., 420, 860-867. 

18.Cox, D.G. et al. (2005) The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet. Genomics., 15, 447-450.

19.Curtin, J.F. et al. (2002) Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods., 265, 49-72 

20.Faltus, T. et al. (2004) Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu–Overexpressing Breast Cancer Cells. Neoplasia.,6, 786-795.

21.Faratian, D. et al. (2009) Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology., 54, 254-257.

22.Friedman, L.M. et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs:  implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA., 102, 1915-1920.

23.Fas, S.C. et al. (2006) Wogonin sensitizes resistant   malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood., 108, 3700-3706.

24.Fukumura, D. et al. (2006) The role of nitric oxide in   tumour progression. Nat. Rev. Cancer., 6, 521-534.

25.Himeji, M. et al. (2007) Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett., 245, 269-274.

26.Holbro, T. et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to  drive breast tumor cell proliferation. Proc. Natl. Acad. Sci USA., 100, 8933-8938.

27.Hong, R.L. et al. (1999) Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. 
Cancer Res., 5, 1884-1891.

28.Huang, Y.T. et al. (1999) Effects of luteolin and  quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.Br. J. Pharmacol., 128, 999-1010.

29.Hussain, S.P. et al. (2003) Radical causes of cancer. Nat. Rev. Cancer., 3, 276-285.  

30.Hynes, N.E. and Lane, H.A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer., 5, 341-354.

31.Hynes, N.E. and MacDonald, G. (2009) ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol., 21, 177-184.

32.Jeong, J.H. et al. (2008) Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J. Cell Biochem., 105, 585-595.

33.Jeong, J.H. et al. (2009) Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J. Cell Biochem., 106, 73-82. 

34.Kachadourian, R. and Day, B.J. (2006) Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med., 41, 65-76.

35.Kachadourian, R. et al., (2007) Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion.Int. J. Oncol., 31, 161-168.

36.Kao, M.C. et al. (1998) The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene., 16, 547-554.

37.Klos, S.K. et al. (2006) ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer Res., 66, 2028-2037.   

38.Lattrich, C. et al. (2008) Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor 39. Oncol. Rep., 19, 811-817.

39.Lee, H.Z. et al. (2005) Baicalein-induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res., 25, 959-964.

40.Lenferink, A.E. et al. (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J., 17, 3385-3397.

41.Leung, H.W. et al. (2007) Inhibition of 12-lipooxygenase during Baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food Chem. Toxicol., 45, 403-411.

42.Li, Y.C. et al. (2008) Baicalein-induced apoptosis via endoplasmic reticulum stress through elevations of reactive oxygen species and mitochondria dependent pathway in mouse-rat hybrid retina ganglion cells (N18). Neurochem. Res., 34, 418-429.

43.Li-Weber, M. (2009) New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat. Rev., 35, 57-68.

44.Li, Y. and Brown, P.H. (2009) Prevention of ER-negative  breast cancer. Recent Results Cancer Res., 181, 121-134.

45.Liu, J.Y. et al. (2009) The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. Cancer  Lett., 273, 273-280.

46.Liu, X. et al. (2009) The nonsteroidal anti-inflammatory Drug tolfenamic acid inhibits BT474 and SKBR3 breast   cancer cell and tumor growth by repressing erbB2  expression. Mol. Cancer Ther., 8, 1207-1217.

47.Ma, Z. et al. (2005) Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood., 105, 3312-3318. 

48.Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signa-ling: navigating downstream. Cell., 129, 1261-1274.

49.Marx, C et al. (2007) Proteasome-regulated ERBB2 and  estrogen receptor pathways in breast cancer. Mol. Pharma col., 71, 1525-1534.

50.Mimnaugh, E.G. et al. (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein tyrosine kinase induced by geldanamycin. J. Biol. Chem., 271, 22796-22801.

51.Miyoshi, N. et al. (2007) Dietary flavonoid apigenin is a potential inducer of intracellular oxidative stress: the role in the interruptive apoptotic signal. Arch. Biochem. Biophys., 466, 274-282.

52.Nelson, D. L. and Cox, M. M. (2004) Lehninger Principle Of Biochemistry, 4th edition. Freeman., Chapter 14, 551.

53.Newman, D.J. and Cragg, G.M. (2007) Natural products as  sources of new drugs over the last 25 years. J. Nat. Prod., 70, 461-477. 

54.Ono, M and Kuwano, M. (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res., 12, 7242-7251.

55.Ou, C.C. et al. (2008) Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis., 29, 299-306.

56.Padhy, L.C. et al. (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell., 28, 865-871.

57.Paik, S. and Liu, E.T. (2000) HER2 as a predictor of therapeutic response in breast cancer. Breast Dis., 11, 91- 102.

58.Pandha, H.S. et al. (1999) Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol., 17, 2180-2189.

59.Penuel, E. et al. (2001) Structural requirements for ErbB2 transactivation. Semin. Oncol., 28, 36-42. 

60.Pinkas-Kramarski, R. et al. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15, 2452-2467.

61.Pidgeon, G.P. et al. (2002) Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipooxygenase inhibition in prostate cancer cells. Cancer Res., 62, 2721-2727.

62.Prat, A. and Baselga, J. (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat. Clin. Pract. Oncol., 5, 531-542.

63.Rao, G.N. et al. (1999) Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Breast Cancer Res. Treat., 58, 241- 254.

64.Ross, J.S. and Fletcher, J.A. (1998) The HER-2/neu onco-gene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells., 16, 413-428.

65.Sakla, M.S. et al. (2007) Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocr., 32, 69-78. 

66.Sergina, N.V. et al. (2007) Escape from HER-family  tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature., 445, 437-441.

67.Sector, N. et al. (2007) HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res., 9, 205.

68.Slamon, D.J. et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science., 235, 177-182.

69.Spiridon, C.I. et al. (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved anti-growth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res., 8, 1720-1730.

70.Storz, P. (2005) Reactive oxygen species in tumor progression. Front. Biosci., 10, 1881-1896.

71.Tzahar, E. et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol., 16, 5276-5287.

72.Wakimoto, N. et al. (2008) Cucurbitacin B has a potent  antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci., 99, 1793-1797. 

73.Way, T.D. et al. (2004) Apigenin induces apoptosis through proteasomal degradation of HER2/neu in  HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J.  Biol. Chem., 279, 4479-4489.

74.Way, T.D. et al. (2005) Degradation of HER2/neu by  apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett., 579, 145-152.

75.Woo, K.J. et al. (2004) Chrysin-induced apoptosis is    mediated through caspase activation and Akt inactivation in U937 leukemia cells. Biochem. Biophys. Res. Commun., 325, 1215-1222.

76.Worthylake, R. et al. (1999) ErbB-2 amplification inhibits own-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. hem., 274, 8865-8874.

77.Xia, W. et al. (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene., 21, 6255-6263. 

78.Yarden, Y. and Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2, 127-137.

79.Yoshida, T. et al. (2008) Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem. Biophys. Res. ommun., 375, 129-133.

80.Yu, D. and Hung, M.C. (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene., 19, 6115-6121.

81.Zhang, D.Y. et al. (2003) Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res., 63, 4037-4043.  

82.Zhang, L. et al. (1995) Suppressed transformation and  induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res., 55, 3890-3896.

83.NCBI Entrez Gene: ERBB2
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=2064&ordinalpos=2&itool=EntrezSystem2.PEntrez.Gene.Gene_ResultsPanel.Gene_RVDocSum#refseq